Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (
NYSE: LLY ) officially announced on January 7, 2026, its definitive agreement to acquire Ventyx Biosciences (
NASDAQ: VTYX ) for approximately $1.2 billion. The all-cash transaction, priced at $14.00 per share, represents
Ventyx’s $1.2B Buyout By Eli Lilly Proves Timing Often Beats Conviction In Biotech Investing — A VC Explains Bottom buyers saw over 2,000% gains, while IPO investors merely broke even after a 90% drawdown, according to Atlas Venture’s Bruce Booth.
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal Lilly will acquire all of the outstanding shares of Ventyx for $14 per share of common stock in an all-cash transaction.
Ventyx Biosciences Stock Jumps On Reports Of Eli Lilly Buyout A deal for Ventyx could be announced imminently, the Wall Street Journal reported, citing people familiar with the matter.
Which stocks have an unusual volume on Friday? Volume analysis on 2025-10-24: stocks with an unusual volume in today's session.
Here are the top movers in Thursday's session. Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Most active stocks in Thursday's session Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Ventyx Stock Is Rallying Thursday: What's Driving The Surge? Ventyx Biosciences Inc (
NASDAQ:VTYX ) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232.
Which stocks are moving on Thursday? Curious about what's happening in today's session? Check out the latest stock movements and price changes.
These stocks are gapping in today's session The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Wondering what's happening in today's pre-market session? Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study The Phase 2 trial showed VTX3232 cut key inflammation markers like hsCRP by about 78% and IL-6 to below risk thresholds, reinforcing its anti-inflammatory potential.
Why Ventyx (VTYX) Shares Soared 86.5% After Hours? Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results.
Which stocks are moving after the closing bell on Wednesday? Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
